Skip to content
Patients
Contact
Patients
Contact
Our Company
Our Science
Pipeline
STEALTH-001 Trial
Careers
News
Our Company
Our Science
Pipeline
STEALTH-001 Trial
Careers
News
Resources
News
In the news
Press release
All
Press release
November 6, 2026
KaliVir Immunotherapeutics Reports 71% Objective Response Rate in Patients with Advanced, Cutaneous Malignancies in Phase 1/1b STEALTH-001 Trial
Read more
Press release
August 19, 2026
KaliVir Immunotherapeutics Announces Closing of $14 Million Series A Extension Financing
Read more
Press release
November 19, 2025
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors
Read more
Press release
October 1, 2025
KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors
Read more
Press release
May 20, 2025
KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors
Read more
Press release
March 25, 2025
KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
Read more
Press release
November 18, 2024
KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates
Read more
Press release
October 8, 2024
KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors
Read more
Press release
September 4, 2024
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Read more
Press release
July 1, 2024
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors
Read more
Press release
February 21, 2024
KaliVir Immunotherapeutics Appoints James M. Burke, M.D., as Chief Medical Officer
Read more
Press release
January 31, 2024
KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses
Read more
Press release
October 24, 2023
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors
Read more
Press release
May 19, 2023
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Read more
Press release
May 10, 2023
KaliVir Immunotherapeutics Appoints Viral Immunotherapy Researcher Grant McFadden, Ph.D., to its Board of Directors
Read more
Press release
May 3, 2023
KaliVir Immunotherapeutics Announces Presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Read more
Press release
April 17, 2023
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Potent Therapeutic Activity for Oncolytic Therapy VET3-TGI at the American Association for Cancer Research (AACR) Annual Meeting
Read more
Press release
December 13, 2022
KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards
Read more
Press release
November 10, 2022
KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting
Read more
Press release
November 1, 2022
KaliVir Appoints Industry Veteran Adina Pelusio as Senior Vice President of Clinical Operations to Lead Clinical Development Pipeline
Read more
Press release
October 24, 2022
KaliVir Immunotherapeutics to Present at 14th International Oncolytic Virotherapy Conference (IOVC)
Read more
Press release
October 5, 2022
KaliVir Immunotherapeutics to Present Data on its Novel Pre-Clinical Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) Annual Meeting
Read more
Press release
May 23, 2022
KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
Read more
Press release
March 16, 2022
KaliVir Immunotherapeutics Closes Series A Financing
Read more
Press release
November 4, 2021
KaliVir Immunotherapeutics Strengthens Intellectual Property Position Through Issuance of Two U.S. Patents.
Read more
Press release
June 17, 2021
KaliVir Immunotherapeutics appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
Read more
Press release
December 7, 2020
KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus.
Read more
In the news
January 1, 2020
How Stephen Thorne and Helena Chaye are blending their talents to create Breakthrough cancer fighting therapies
Read more